June 1, 2024Journal of Clinical Oncology

A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.

View Full Paper

Ask AI

Bookmark

Complete and overall tumor responses occurred rapidly following non-gene-edited anti-CD19 allogeneic cellular therapy in patients with extranodal bulky lesions.
Randomized trial data showed an overall response rate of 90% at day 28, confirming rapid tumor debulking using novel allogeneic car t-cell therapy infusions.
Single-center findings highlight manageable cytokine release syndrome without grade 3 events, supporting this intracellular retention platform for aggressive disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates high response rates with allogeneic CAR T-cell therapy in extranodal bulky B-cell lymphoma, suggesting a viable bridge to disease consolidation.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e6706cb6db6435875fb2dc https://doi.org/10.1200/jco.2024.42.16_suppl.e19007

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates high response rates with allogeneic CAR T-cell therapy in extranodal bulky B-cell lymphoma, suggesting a viable bridge to disease consolidation.

A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.

Key Points

Discussion

Implication

Cite This Study

A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider